Innovative Medicines)

This procedure concerns the formal approval of how the Joint Technology Initiative on Innovative Medicines managed its budget for the 2009 financial year. This process ensures that EU funds were spent legally, regularly, and according to the intended goals of the partnership.

This affects the management of the Joint Undertaking and the public-private partnerships involved in pharmaceutical research, ensuring financial accountability for EU taxpayers.